Hetero launches biosimilar Rituximab in India
Hetero has launched biosimilar Rituximab in India used for treatment of certain types of cancers and rheumatoid arthritis under the brand name 'Maball'.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Arthritis | Biotechnology | Cancer | Cancer & Oncology | Pharmaceuticals | Rheumatoid Arthritis | Rheumatology | Rituxan